Danske Bank A S Sells 16,168 Shares of DaVita Inc. $DVA

Danske Bank A S cut its holdings in DaVita Inc. (NYSE:DVA) by 75.3% during the fourth quarter, HoldingsChannel reports. The firm owned 5,300 shares of the company’s stock after selling 16,168 shares during the period. Danske Bank A S’s holdings in DaVita were worth $602,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Elevation Wealth Partners LLC increased its position in DaVita by 147.3% during the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after acquiring an additional 165 shares during the period. Canada Pension Plan Investment Board acquired a new position in DaVita during the 2nd quarter valued at $43,000. iSAM Funds UK Ltd acquired a new stake in DaVita in the 3rd quarter worth $46,000. Stance Capital LLC bought a new position in shares of DaVita during the 3rd quarter worth about $47,000. Finally, Camelot Portfolios LLC bought a new position in shares of DaVita during the 4th quarter worth about $57,000. 90.12% of the stock is currently owned by institutional investors.

Key DaVita News

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Q1 earnings and revenue beat street estimates; EPS $2.87 vs. consensus and revenue topped expectations, showing operational strength. DaVita HealthCare (DVA) Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Company raised its annual adjusted profit forecast, citing steady/strong demand for dialysis services — a clear driver for higher forward earnings expectations. DaVita lifts annual profit forecast on strong demand for dialysis services
• Positive Sentiment: Company commentary and PR emphasize clinical performance and operating rigor, reinforcing confidence in recurring dialysis revenue and margin durability. DaVita Inc. 1st Quarter 2026 Results
• Neutral Sentiment: Guidance range of $14.10–$15.20 roughly lines up with consensus (≈$14.13 midpoint), so while management raised the top-line outlook, the midpoint is close to expectations — limits the surprise factor. MarketBeat Q1 release & guidance
• Neutral Sentiment: Elevated intraday trading volume (~2M vs. ~985k average) indicates increased attention and liquidity, which can amplify price moves in either direction. DaVita’s Q1 CY2026 beats on revenue
• Negative Sentiment: Despite the beat, reported net margin was modest (≈5.5%) and the company showed a negative return on equity figure, which may concern some investors about capital structure or one-time items; watch commentary from the call for drivers. DaVita HealthCare: Q1 Earnings Snapshot

Analyst Ratings Changes

Several research analysts have recently issued reports on DVA shares. Truist Financial set a $158.00 price objective on shares of DaVita in a report on Thursday, February 5th. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Zacks Research downgraded shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Barclays boosted their price objective on shares of DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 3rd. Finally, UBS Group boosted their price objective on shares of DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $155.80.

DaVita Stock Performance

NYSE:DVA opened at $156.98 on Wednesday. The company has a 50-day moving average of $151.30 and a 200-day moving average of $131.73. The company has a market capitalization of $10.49 billion, a price-to-earnings ratio of 15.84, a PEG ratio of 0.54 and a beta of 0.84. DaVita Inc. has a 52 week low of $101.00 and a 52 week high of $159.42.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. The company had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The firm’s revenue for the quarter was up 6.0% compared to the same quarter last year. During the same period last year, the firm earned $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Sell-side analysts forecast that DaVita Inc. will post 14.16 EPS for the current year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.